Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Warby Parker (WRBY)

Tipranks - Tipranks - Wed Feb 25, 10:44AM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Protara Therapeutics (TARA – Research Report), Warby Parker (WRBY – Research Report) and Palvella Therapeutics (PVLA – Research Report) with bullish sentiments.

Claim 50% Off TipRanks Premium

Protara Therapeutics (TARA)

In a report released today, Andres Y. Maldonado from H.C. Wainwright maintained a Buy rating on Protara Therapeutics, with a price target of $23.00. The company’s shares closed last Tuesday at $5.95.

According to TipRanks.com, Maldonado is a 5-star analyst with an average return of 49.2% and a 56.4% success rate. Maldonado covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, Monopar Therapeutics Inc, and Syndax Pharmaceuticals. ;'>

Currently, the analyst consensus on Protara Therapeutics is a Strong Buy with an average price target of $25.60, which is a 309.6% upside from current levels. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a price target.

See today’s best-performing stocks on TipRanks >>

Warby Parker (WRBY)

In a report issued on February 19, Dylan Carden from William Blair maintained a Buy rating on Warby Parker. The company’s shares closed last Tuesday at $22.32.

According to TipRanks.com, Carden is a 4-star analyst with an average return of 9.2% and a 55.4% success rate. Carden covers the NA sector, focusing on stocks such as Savers Value Village Inc., National Vision Holdings, and Brilliant Earth Group. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Warby Parker with a $31.00 average price target, implying a 39.6% upside from current levels. In a report issued on February 10, Telsey Advisory also maintained a Buy rating on the stock with a $32.00 price target.

Palvella Therapeutics (PVLA)

Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Palvella Therapeutics today and set a price target of $250.00. The company’s shares closed last Tuesday at $116.36.

According to TipRanks.com, Samimy is a 5-star analyst with an average return of 16.3% and a 50.1% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Mineralys Therapeutics, Inc., and Supernus Pharmaceuticals. ;'>

Currently, the analyst consensus on Palvella Therapeutics is a Strong Buy with an average price target of $202.80, implying a 79.5% upside from current levels. In a report issued on February 9, H.C. Wainwright also maintained a Buy rating on the stock with a $200.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).